Partial scalp alopecia is a common problem that can lead to severe social and psychological problems. Tissue expansion, although an old concept, provides a surgical alternative to manage areas of alopecia. We describe a case of alopecia secondary to repaired occipital encephalocele that was successfully treated using tissue expansion technique.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Trachyonychia secondary to pediatric alopecia areata responding to oral tofacitinib therapy: a case report and review of literature.
Int J Dermatol
January 2025
Department of Dermatology, IMS and SUM Hospital, Bhubaneswar, India.
Sublingual Minoxidil Increases Fibre Diameter in Male Androgenetic Alopecia. - A proxy for Reversal of Hair Follicle Miniaturization.
Clin Exp Dermatol
January 2025
Tricholab AB, Warsaw, Poland.
Background: The histological hallmark of male androgenetic alopecia (MAGA) is transformation of terminal follicles into miniaturized secondary-vellus follicles. As the volume of the dermal papilla determines the size of the hair bulb and hair fibre diameter, any treatment induced increase in fibre diameter could be used as a proxy for reversal of hair follicle miniaturization. While clinical trials with minoxidil topical solution in MAGA do not demonstrate increased fibre diameter, vellus-to-terminal reconversion is shown in a humanized mouse model treated with MXL.
View Article and Find Full Text PDFBaricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study.
J Dermatolog Treat
December 2025
Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Baricitinib, a JAK 1/2 inhibitor, is approved for treating severe alopecia areata (AA). This study aimed to evaluate the long-term effectiveness and safety of baricitinib in a real-world setting over 52 weeks. This multicenter retrospective study included 96 adult patients diagnosed with severe AA from 11 Italian Dermatology Units.
View Article and Find Full Text PDFA scoping review of alopecia areata and its relationship to COVID-19 vaccinations.
Arch Dermatol Res
December 2024
Albert Einstein College of Medicine, Montefiore Medical Center, 1300 Morris Park Avenue, Bronx, NY, 10461, USA.
In response to the COVID-19 pandemic several vaccines were produced, including novel mRNA and viral vector-based vaccines. Though COVID-19 had its own associated dermatological sequelae, the vaccines were associated with a new set of cutaneous side effects, including hypersensitivity reactions, vasculitis, and autoimmune-mediated reactions. Notably, alopecia areata (AA) was reported in several patients closely following a COVID-19 vaccine, especially in those with a personal or family history of AA.
View Article and Find Full Text PDFOptimal Treatment for Post-Surgical Cicatricial Alopecia: Autologous Hair Transplantation?
J Craniofac Surg
December 2024
Department of Dermatological Surgery, Shenyang Seventh People's Hospital, Shenyang, Liaoning, China.
Background And Rationale: Scarring alopecia significantly impacts patients' appearance and psychological well-being. Surgery is a common cause of scarring alopecia, making positive treatment crucial for patients' overall health.
Objective: To investigate the clinical efficacy of autologous follicular unit extraction (FUE) transplantation for postoperative secondary stable scarring alopecia and evaluate its effectiveness.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!